+1 (314) 370-6046 or
Contact Us
  • Argentina
  • Australia
  • Austria
  • Bahrain
  • Belgium
  • Brazil
  • Bulgaria
  • Cameroon
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Cyprus
  • Czech Republic
  • Denmark
  • Ecuador
  • Egypt
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Ireland
  • Israel
  • Italy
  • Japan
  • Kazakhstan
  • Kuwait
  • Latvia
  • Lithuania
  • Luxembourg
  • Macedonia
  • Malaysia
  • Malta
  • Mexico
  • Monaco
  • Morocco
  • Netherlands
  • New Zealand
  • Nigeria
  • Norway
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Russia
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • South Korea
  • Spain
  • Sri Lanka
  • Sweden
  • Switzerland
  • Taiwan
  • Thailand
  • Turkey
  • Ukraine
  • UAE
  • United Kingdom
  • United States
  • Venezuela
  • Vietnam

Anti-Rituximab Antibody [MB2A4] (HRP) (A281065)

$905

Rat monoclonal [MB2A4] antibody to Rituximab (HRP) for ELISA.

Alternative Formats and ConjugatesAlternative Formats

Shipping Information

$40
Dispatched from St. Louis, MO.
Lead Time: 5-7 business days.
Name
Anti-Rituximab Antibody [MB2A4] (HRP)
Description
Rat monoclonal [MB2A4] antibody to Rituximab (HRP).
Specificity
This antibody recognises the monoclonal antibody drug rituximab. The antibody can be used to measure the levels of rituximab and biosimilar products in bioanalytical assays. recognises ocrelizumab, a second-generation humanized anti-CD20 antibody that binds to an epitope on CD20 that is identical or overlapping with the rituximab epitope. Clone MB2A4 has been used in ELISA to monitor the levels of rituximab in patient serum following therapy (Cragg et al. 2004 and Hampson et al. 2010).Clone MB2A4 has been used to detect rituximab bound to the surface of the Raji B cell line, however detection of rituximab bound in vivo to B-CLL cells has not been demonstrated. It is possible that complement deposition on rituximab opsonised cells inhibits binding of the Anti-Rituximab Antibody to cell bound rituximab. Inhibition experiments carried out with Daudi cells demonstrated that this antibody is inhibitory at a ratio of 5:1 antibody:rituximab, but does not inhibit rituximab binding to CD20 at a ratio of 1:1.Rituximab (reference product branded as Rituxan) is a chimeric mouse/human monoclonal antibody approved for the treatment of certain autoimmune diseases and cancer, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. The antibody is specific for the cell surface protein CD20, which is widely expressed on B cells. Through three different mechanisms of action it eliminates B cells from the body, enabling the development of a new population of healthy B cells.View a summary of all Anti-Rituximab Antibodies.
Applications
ELISA
Dilutions
ELISA: 1:20,000 - 1:200,000
Immunogen
F(ab')2 fragment of Rituximab.
Host
Rat
Clonality
Monoclonal
Clone ID
MB2A4
Isotype
IgG2a
Conjugate

HRP

Purification
Protein G affinity chromatography of tissue culture supernatant.
Concentration
1 mg/ml
Product Form
Liquid
Formulation
Supplied in Phosphate Buffered Saline with 0.09% Sodium Azide.
Storage
Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.
General Notes
Rat Anti-Rituximab Antibody, clone MB2A4, is an anti-idiotypic antibody that recognizes the monoclonal antibody drug rituximab. The antibody can be used to measure the levels of rituximab and biosimilar products in bioanalytical assays. Rat Anti-Rituximab Antibody also recognizes ocrelizumab, a second-generation humanized anti-CD20 antibody that binds to an epitope on CD20 that is identical or overlapping with the rituximab epitope. Clone MB2A4 has been used in ELISA to monitor the levels of rituximab in patient serum following therapy (Cragg et al. 2004 and Hampson et al. 2010). Clone MB2A4 has been used to detect rituximab bound to the surface of the Raji B cell line, however detection of rituximab bound in vivo to B-CLL cells has not been demonstrated. It is possible that complement deposition on rituximab opsonised cells inhibits binding of the Anti-Rituximab Antibody to cell bound rituximab (Beum et al. 2004). Inhibition experiments carried out with Daudi cells demonstrated that this antibody is inhibitory at a ratio of 5:1 antibody:rituximab, but does not inhibit rituximab binding to CD20 at a ratio of 1:1.Rituximab (reference product branded as Rituxan) is a chimeric mouse/human monoclonal antibody approved for the treatment of certain autoimmune diseases and cancer, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. The antibody is specific for the cell surface protein CD20, which is widely expressed on B cells. Through three different mechanisms of action it eliminates B cells from the body, enabling the development of a new population of healthy B cells.View a summary of all Anti-Rituximab Antibodies.
Disclaimer
This product is for research use only. It is not intended for diagnostic or therapeutic use.
Publishing research using Anti-Rituximab Antibody [MB2A4] (HRP) (A281065)? Please let us know so that we can list the citation on this page.